Millipore debuts GPCRProfiler
Massachusetts, USA-headquartered Millipore Corp has announced the availability of GPCRProfiler screening, an innovative service for selectivity screening, characterization of lead compounds and screening of focused glycoprotein-coupled receptor libraries. GPCRProfiler screening more accurately characterizes lead compounds than traditional binding methods by providing comprehensive functional data that enables pharmaceutical and biotechnology companies to accelerate their lead optimization efforts, according to the firm.
The GPCRProfiler package includes: selectivity screening for off-target effects; IC50 dose response analysis; and screening of focused libraries against single or multiple targets. The GPCRProfiler service is the first complete functional cell-based assay platform, comments Millipore.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze